SNHL results from irreversible damage or degeneration of inner-ear sensory hair cells and spiral ganglion neurons, driven by genetic mutations, noise exposure, ototoxic medications, viral infections, and aging. Despite its global prevalence and profound impact on quality of life, there are currently no FDA-approved disease-modifying treatments for any form of hearing loss.

We are advancing a differentiated pipeline of first-in-class therapeutics designed to repair and regenerate inner-ear sensory hair cells and auditory nerve fibers, addressing the root causes of SNHL. Our platform integrates multiple complementary modalities, including:

AAV-based gene therapy – Targeted delivery of therapeutic genes to specific inner-ear cell populations using adeno-associated viral vectors. AAV therapies have demonstrated clinical promise in congenital hearing loss (e.g., OTOF-related), and we aim to extend this paradigm to adult-onset, acquired hearing loss, with plans to initiate clinical proof-of-concept studies.

RNA and small-molecule therapeutics – Non-viral approaches delivered via lipid nanoparticles (LNPs) and other scalable platforms, enabling cost-effective manufacturing and broader patient access.

Salubritas has validated multiple therapeutic candidates in robust preclinical models and is currently advancing lead programs through optimization. Over the next three years, the company plans to nominate at least two development candidates and complete IND-enabling studies, positioning Salubritas for entry into clinical trials and the establishment of a new therapeutic category in hearing restoration.